The IQS Business Foundation has been joined by new member Grupo Italfarmaco, an international pharmaceutical laboratory based in Spain.
The IQS Business Foundation has been joined by new member Grupo Italfarmaco, an international pharmaceutical laboratory based in Spain. The company's membership in the IQS Business Foundation was formalized through an institutional event held on 4 October at the IQS campus. Attending the event on behalf of Grupo Italfarmaco were Santiago Carolá, Deputy General Manager and an IQS Alumnus in Chemical Engineering from the class of 2000, and Verónica Somodevilla, Director of Institutional Relations. On behalf of IQS, Dr Salvador Borrós, Director of IQS, and Rosa Curt, Director of the IQS Business Foundation, were present.
The Italfarmaco Group's main activity is the marketing of prescription specialties and the research, development, and manufacturing of medicines. Since its creation, the Italfarmaco Group has been committed to a constant search for improvements in existing medical treatments and its efforts have always focused on research.
At the group level, it boasts a consolidated position in the areas of Gynaecology, Neurology, Dermatology, Bone Metabolism, the Digestive System, the Respiratory System, Psychiatry, and Paediatrics.
Italfarmaco has recently acquired 100% of the Spanish pharmaceutical laboratory LACER, a healthcare and personal hygiene company headquartered in Barcelona with an industrial plant in Cerdanyola del Vallès. In doing so, it is reinforcing its presence on the health care market, where it already markets well-established brands such as Natalben, Prodefen, Neuralex, Oniria, Aloclair Plus, and Ainara.
Currently, the Madrid industrial plant manufactures liquid, granular, and semi-solid pharmaceutical specialties for the entire Group and also has manufacturing contracts with 30 different companies in Spain, Europe, and around the world.